Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novo Nordisk 3Q

In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novo Nordisk 3Q09

3Q Revenues: $2.5 billion (+11%)

3Q Earnings: $539.7 million (+3%)

YTD Revenues: $7.4 billion (+16%)

YTD Earnings: $1.7 million (+21%)

Comments: In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%). NovoSeven sales were up 8%, Norditropin sales were up 14%, and Hormone replacement therapy sales were up 12%. North America sales were up 20%. Sales in Europe were up 2%. International Operations were up 10% and Japan and Oceania sales were up 20%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters